Evaluate Early Invasive Strategy for Patients With STEMI Presenting 24-48 Hours From Symptom Onset

Inclusion Criteria: 1. Age: 18 or over and less than 75 years old; 2. ECG: a) ≥2 mm ST-segment elevation in 2 contiguous precordial leads or ≥1 mm ST-segment elevation in 2 contiguous extremity leads; or b) new or presumable new left bundle branch block in the presence of typical symptoms; 3. Patents with STEMI with symptom onset between 24 and 48 hours before randomization; 4. Signed informed consent form prior to trial participation. Exclusion Criteria: 1. Patents with STEMI with symptom onset \<24h or \>48h or uncertain time onset. 2. Prior administration of thrombolytic therapy or attempted PCI before randomization; 3. Presence of indications for primary PCI, such as persistent chest pain, cardiogenic shock, life-threatening arrhythmias or cardiac arrest, severe acute heart failure, and mechanical complications; 4. Coagulopathy, active peptic ulcer, history of cerebral or subarachnoid hemorrhage, stroke within 6 months, other contraindications for antiplatelet or anticoagulant therapy; 5. Known intolerance to antiplatelet (e.g. aspirin, clopidogrel, ticagrelor) and anticoagulant therapy (e.g. heparin, bivalirudin); 6. Presence of contraindications for CMR; 7. Congenital heart disease or severe valvular disease; 8. eGFR \<30 ml/min/1.73 m2; 9. History of malignant tumors; 10. Combined with other diseases and life expectancy ≤12 months; 11. Pregnancy; 12. Inclusion in another clinical trial; 13. Inability to provide informed consent or not available for follow-up judged by investigator.